---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-24-000026"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:07:17.343029+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics Q2 2024 net loss $17.2M; positive clinical data for WTX-124 and WTX-330

## Summary
- Net loss of $17.2M in Q2 2024 vs $5.1M in Q2 2023; R&D expenses rose to $15.3M from $9.6M.
- Cash and equivalents $135.3M at June 30, 2024; sufficient to fund operations through at least Q1 2026.
- WTX-124 monotherapy achieved 3 objective responses, including 1 complete response at 18 mg IV Q2W RDE.
- WTX-330 showed 1 unconfirmed partial response in melanoma; therapeutically relevant exposure levels achieved.
- Updated WTX-124 combination data and expansion arms expected H2 2024; WTX-330 data in Q4 2024.

## SEC filing metadata
- accession: 0001785530-24-000026
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553024000026/0001785530-24-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553024000026/howl-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-24-000026
- JSON: https://secwatch.observer/filing/0001785530-24-000026.json
- Plain text: https://secwatch.observer/filing/0001785530-24-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.